<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00378911</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02702</org_study_id>
    <secondary_id>NCI-2012-02702</secondary_id>
    <secondary_id>CDR0000495190</secondary_id>
    <secondary_id>GOG-0231C</secondary_id>
    <secondary_id>GOG-0231C</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00378911</nct_id>
  </id_info>
  <brief_title>Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus</brief_title>
  <official_title>A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well sunitinib works in treating patients with recurrent&#xD;
      or persistent leiomyosarcoma of the uterus. Sunitinib may stop the growth of tumor cells by&#xD;
      blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the activity of sunitinib malate, in terms of rate of progression-free survival for&#xD;
      ≥ 6 months and objective tumor response, in patients with recurrent or persistent&#xD;
      leiomyosarcoma of the uterus who have received 1 or 2 prior cytotoxic therapies.&#xD;
&#xD;
      II. Determine the frequency and severity of adverse events.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the duration of progression-free survival and overall survival.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients receive oral sunitinib malate once daily on&#xD;
      days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years and&#xD;
      then every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From study entry until disease progression, death or date of last contact., assessed up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective tumor response according to GOG RECIST criteria</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of adverse events as assessed by CTCAE v 3.0</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The frequency and severity of all toxicities will be tabulated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of progression-free survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Characterized graphically and using descriptive statistics such as median survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall survival</measure>
    <time_frame>From entry into the study to death or the date of last contact, assessed up to 5 years</time_frame>
    <description>Characterized graphically and using descriptive statistics such as median survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Recurrent Uterine Sarcoma</condition>
  <condition>Uterine Leiomyosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (sunitinib malate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (sunitinib malate)</arm_group_label>
    <other_name>SU11248</other_name>
    <other_name>sunitinib</other_name>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed leiomyosarcoma of the uterus&#xD;
&#xD;
               -  Recurrent or persistent disease&#xD;
&#xD;
               -  Refractory to curative therapy or established treatments&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by&#xD;
             conventional techniques or ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Ascites and pleural effusions are not considered measurable disease&#xD;
&#xD;
          -  Must have ≥ 1 target lesion to assess response&#xD;
&#xD;
               -  Tumors in a previously irradiated field are considered non-target lesions unless&#xD;
                  there is documented progression or biopsy-confirmed persistence ≥ 90 days after&#xD;
                  completion of radiotherapy&#xD;
&#xD;
          -  Received at least 1 but no more than 2 prior cytotoxic regimens&#xD;
&#xD;
               -  Initial treatment may have included high-dose chemotherapy, consolidation, or&#xD;
                  extended therapy administered after surgery or nonsurgical assessment&#xD;
&#xD;
               -  Cytotoxic regimens may have included any agent that targets the genetic and/or&#xD;
                  mitotic apparatus of dividing cells, resulting in dose-limiting toxicity to the&#xD;
                  bone marrow and/or gastrointestinal mucosa&#xD;
&#xD;
          -  Not a candidate for a higher priority GOG protocol&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  GOG performance status 0-2 (for patients who have received 1 prior regimen) OR GOG 0-1&#xD;
             (for patients who have received 2 prior regimens)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  SGOT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 1.5 times ULN&#xD;
&#xD;
          -  QTc &lt; 500 msec&#xD;
&#xD;
          -  LVEF normal by echocardiogram&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 1 month after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Patients with a pre-existing thyroid abnormality unable to maintain normal thyroid&#xD;
             function with medication are not eligible&#xD;
&#xD;
          -  No significant EKG abnormalities (i.e., no history of serious ventricular arrhythmia&#xD;
             OR EKG with ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)&#xD;
&#xD;
          -  No sensory or motor neuropathy &gt; grade 1&#xD;
&#xD;
          -  No NYHA class III-IV congestive heart failure&#xD;
&#xD;
               -  NYHA class II cardiac dysfunction allowed&#xD;
&#xD;
               -  History of NYHA class II heart failure that is asymptomatic on treatment allowed&#xD;
&#xD;
          -  No active infection requiring antibiotics&#xD;
&#xD;
          -  No other invasive malignancies within the past 5 years except for nonmelanoma skin&#xD;
             cancer&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to sunitinib malate&#xD;
&#xD;
          -  No poorly controlled hypertension (i.e., systolic blood pressure [BP] ≥ 140 mm Hg or&#xD;
             diastolic BP ≥ 90 mm Hg)&#xD;
&#xD;
          -  No gastrointestinal tract disease resulting in an inability to take oral medication&#xD;
&#xD;
          -  No requirement for IV alimentation&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No other condition that would impair ability to swallow and retain study drug&#xD;
&#xD;
          -  No serious or nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within&#xD;
             the past 28 days&#xD;
&#xD;
          -  No cerebrovascular accident or transient ischemic attack within the past year&#xD;
&#xD;
          -  No myocardial infarction, cardiac arrhythmia, stable or unstable angina, or&#xD;
             symptomatic congestive heart failure within the past year&#xD;
&#xD;
          -  No pulmonary embolism within the past year&#xD;
&#xD;
          -  No uncontrolled illness including, but not limited to, any of the following:&#xD;
&#xD;
               -  Ongoing or active infections&#xD;
&#xD;
               -  Psychiatric illness or social situations that would preclude study compliance&#xD;
&#xD;
          -  Recovered from prior surgery, chemotherapy, or radiotherapy&#xD;
&#xD;
          -  Prior anthracycline exposure and central thoracic radiation that included the heart&#xD;
             allowed provided patient has New York Heart Association (NYHA) class II cardiac&#xD;
             function&#xD;
&#xD;
          -  At least 1 week since prior hormonal therapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin C)&#xD;
             or radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
          -  At least 3 years since prior radiotherapy for localized cancer of the breast, head and&#xD;
             neck, or skin and no recurrent or metastatic disease&#xD;
&#xD;
          -  At least 3 years since prior adjuvant chemotherapy for localized cancer of the breast&#xD;
             and no recurrent or metastatic disease&#xD;
&#xD;
          -  No prior radiotherapy to any portion of the abdominal cavity or pelvis unless for&#xD;
             treatment of leiomyosarcoma&#xD;
&#xD;
          -  No prior chemotherapy to any portion of the abdominal cavity or pelvis unless for&#xD;
             treatment of leiomyosarcoma&#xD;
&#xD;
          -  No prior noncytotoxic chemotherapy for recurrent or persistent disease&#xD;
&#xD;
          -  No prior surgical procedures affecting absorption&#xD;
&#xD;
          -  No coronary or peripheral artery bypass graft or stenting within the past year&#xD;
&#xD;
          -  No other prior antiangiogenic agents (e.g., bevacizumab, sorafenib, pazopanib,&#xD;
             AZD2171, vatalanib, or vascular endothelial growth factor [VEGF] Trap)&#xD;
&#xD;
          -  No other prior cancer treatment that would preclude study treatment&#xD;
&#xD;
          -  At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Azole fungals (e.g., ketoconazole or itraconazole)&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  HIV protease inhibitors (e.g., indinavir, saquinavir, ritonavir, atazanavir, or&#xD;
                  nelfinavir)&#xD;
&#xD;
               -  Delavirdine&#xD;
&#xD;
          -  At least 12 days since prior and no concurrent CYP3A4 inducers, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Efavirenz&#xD;
&#xD;
               -  Tipranavir&#xD;
&#xD;
          -  No concurrent proarrhythmic potential agent, including any of the following:&#xD;
&#xD;
               -  Terfenadine&#xD;
&#xD;
               -  Quinidine&#xD;
&#xD;
               -  Procainamide&#xD;
&#xD;
               -  Disopyramide&#xD;
&#xD;
               -  Sotalol&#xD;
&#xD;
               -  Probucol&#xD;
&#xD;
               -  Bepridil&#xD;
&#xD;
               -  Haloperidol&#xD;
&#xD;
               -  Risperidone&#xD;
&#xD;
               -  Indapamide&#xD;
&#xD;
               -  Flecainide&#xD;
&#xD;
          -  No concurrent therapeutic coumarin-derivative anticoagulants, such as warfarin&#xD;
&#xD;
               -  Doses ≤ 2 mg daily allowed for prophylaxis of thrombosis&#xD;
&#xD;
               -  Low molecular weight heparin allowed provided PT INR ≤ 1.5&#xD;
&#xD;
          -  No concurrent amifostine or other protective agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martee Hensley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 19, 2006</study_first_submitted>
  <study_first_submitted_qc>September 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2006</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

